Sugi Predict

Sugi Predict / Compounds / SCHEMBL3267439

SCHEMBL3267439

SCHEMBL3267439

Cc1cc(B(O)O)ccc1C#N

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 5/20 0.47
▸ TSHR P16473 1/20 0.43
▸ CA2 P00918 2/20 0.41
▸ LPL P06858 1/20 0.41
▸ LIPG Q9Y5X9 1/20 0.41
▸ ORAI1 Q96D31 1/20 0.37
▸ ORAI2 Q96SN7 1/20 0.37
▸ ORAI3 Q9BRQ5 1/20 0.37
▸ TRPV6 Q9H1D0 1/20 0.37
▸ CA1 P00915 1/20 0.36
▸ S1PR3 Q99500 1/20 0.36
▸ AR P10275 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ EGLN2 Q96KS0 1/20 0.34
▸ TTR P02766 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953195 1.00 ENPP2 (0.47) ENPP2TSHRCA2LPLLIPG
SCHEMBL585744 0.84 ENPP2 (0.47) ENPP2TSHRCA2LPLLIPG
SCHEMBL15156401 0.81 ENPP2 (0.52) ENPP2TSHRCA2CA1TTR
SCHEMBL22683618 0.78 ENPP2 (0.48) ENPP2TSHRCA2CA1TTR
SCHEMBL29955038 0.78 ENPP2 (0.48) ENPP2TSHRCA2CA1TTR
SCHEMBL29825814 0.76 TRPV4 (0.52) ENPP2
SCHEMBL14120471 0.76 TRPV4 (0.52) ENPP2S1PR3ARTTR
SCHEMBL211234 0.76 TRPV4 (0.52) ENPP2
SCHEMBL3267786 0.76 ENPP2 (0.42) ENPP2CA2LPLLIPGCA1
SCHEMBL29821479 0.76 ALDH1A1 (0.56) ENPP2CA2CA1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2025-10-14 — — US disclosed
EP-4222155-B1 MONONUCLEAR TRIPODAL HEXADENTATE IRIDIUM COMPLEXES FOR USE IN OLEDS UDC IRELAND LTD (IE) 2025-06-11 — — EP disclosed
US-20240368147-A1 CYCLIN K DEGRADER ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2024-11-07 — — US disclosed
EP-4382519-A1 CYCLIN K DEGRADATION AGENT Adlai Nortye Biopharma Co., Ltd. (CN) 2024-06-12 — — EP disclosed
EP-3856348-B1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS INCYTE CORP (US) 2024-01-03 — — EP disclosed
US-20230331754-A1 MONONUCLEAR TRIPODAL HEXADENTATE IRIDIUM COMPLEXES FOR USE IN OLEDS UDC IRELAND LIMITED (IE) 2023-10-19 — — US disclosed
CN-116848099-A Cyclin K degrading agent 杭州阿诺生物医药科技有限公司 2023-10-03 — — CN disclosed
US-20230192706-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-06-22 — — US disclosed
US-20230134116-A1 CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS PROTOMER TECHNOLOGIES, INC. 2023-05-04 — — US disclosed
US-20230134116-A1 CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS PROTOMER TECHNOLOGIES, INC. 2023-05-04 — — US disclosed
WO-2014201206-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2014-12-18 — — WO disclosed
US-20140371201-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. 2014-12-18 — — US disclosed
US-20140371201-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. 2014-12-18 — — US disclosed
US-7799779-B2 Substituted piperidines as renin inhibitors NOVARTIS AG (CH) 2010-09-21 — — US disclosed
EP-1863802-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2010-06-16 — — EP disclosed
US-20090306064-A1 Substituted Piperidines as Renin Inhibitors NOVARTIS AG (CH) 2009-12-10 — — US disclosed
EP-1987834-A2 Substituted piperidines as therapeutic compounds Speedel Experimenta AG (CH) 2008-11-05 — — EP disclosed
EP-1863802-A1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS Speedel Experimenta AG (CH) 2007-12-12 — — EP disclosed
WO-2006134481-A1 INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 PFIZER INC. (US) 2006-12-21 — — WO disclosed
WO-2006103273-A1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306064-A1 Substituted Piperidines as Renin Inhibitors REN, AGTR1, ACE ENPP2 2338/4885TSHR 824/4885CA2 465/4885
US-20240368147-A1 CYCLIN K DEGRADER CCNK, CCNI, CDK1 ENPP2 2764/4885TSHR 3183/4885CA2 4418/4885
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 ENPP2 440/4885TSHR 3771/4885CA2 1619/4885
US-20230192706-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CDK2, CCNI, CDK1 ENPP2 3647/4885TSHR 3491/4885CA2 2665/4885
US-20230331754-A1 MONONUCLEAR TRIPODAL HEXADENTATE IRIDIUM COMPLEXES FOR USE IN OLEDS OCIAD1, OCIAD2, NUDT1 ENPP2 163/4885TSHR 3510/4885CA2 3794/4885
US-20140371201-A1 BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS SCN7A, TRPV1, TRPV5 ENPP2 815/4885TSHR 4247/4885CA2 172/4885
US-20230134116-A1 CONJUGATES FOR SELECTIVE RESPONSIVENESS TO VICINAL DIOLS GPR119, GLP1R, IAPP ENPP2 995/4885TSHR 631/4885CA2 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.